McAlpine's Multiple Sclerosis
Elsevier - Health Sciences Division (Verlag)
978-0-323-93634-7 (ISBN)
- Noch nicht erschienen (ca. April 2026)
- Versandkostenfrei
- Auch auf Rechnung
- Artikel merken
Discusses recent advances in both diagnosis and management, including improved understanding of MS in childhood and the elderly, anti-MOG disease, treatments of progressive MS, remyelination and neuroprotective therapies, and more
Offers authoritative reviews of the current literature, placed in historical context
Features more than 550 high-quality illustrations clarifying important scientific and clinical concepts
Provides the most authoritative and comprehensive history of the understanding of the disease
Uses a remarkably clear presentation to make complicated data easier to understand
An eBook version is included with purchase. The eBook allows you to access all of the text, figures and references, with the ability to search, customize your content, make notes and highlights, and have content read aloud. Additional digital ancillary content may publish up to 6 weeks following the publication date
Alasdair Coles, Ph.D. is a Professor of Neuroimmunology in the Division of Clinical Neurosciences at the University of Cambridge. Has been doing MS research in Cambridge since 1994. He is also a consultant neurologist. With Alastair Compston, he was very involved in the development of alemtuzumab as a treatment of MS. He is employed as a senior lecturer by Cambridge University and has a small research team managing clinical trials and doing human immunological laboratory work. He does clinical work for two days a week as a consultant neurologist at Addenbrooke's and Peterborough Hospitals, is one of the medical advisers to the Multiple Sclerosis Society of the UK, and advises several pharmaceutical companies. Alastair Compston, PhD is Emeritus Professor of Neurology in the Division of Clinical Neurosciences at the University of Cambridge. Compston's research focuses on the clinical science of human demyelinating disease including the discovery of genetic risk factors for multiple sclerosis and the introduction of alemtuzumab. Compston was formerly Professor of Neurology at the University of Wales, president of the European Neurological Society and the Association of British Neurologists, and editor of the journal Brain. Compston's work has been recognised by prizes including the Charcot Award; the K-J Zülch Prize; the World Federation of Neurology Medal; the John Dystel Prize; the Richard and Mary Cave Award of the Multiple Sclerosis Society of Great Britain; the Hughlings Jackson Medal; the Galen Medal; and the Association of British Neurologists Medal. Compston was elected a Fellow of the Royal Society (FRS) in 2016and appointed Commander of the Order of the British Empire (CBE) in the 2016 New Year Honours. Catherine Lubetzki, MD, PhD, is a professor of neurology at the Pierre and Marie Curie University as well as head of the Department of Neurological Diseases at the Salpêtrière Hospital. She coordinates the Clinical Research Centre for Multiple Sclerosis at Salpêtrière. Professor Rocca is Head of the "Neuroimaging of CNS White Matter Unit, Division of Neuroscience, Scientific Institute Ospedale San Raffaele, Milan, Italy and Associate Professor of Neurology at Vita-Salute San Raffaele University. Her activity is mainly focused on the application of structural and functional MR based techniques to improve the understanding of CNS function and dysfunction in healthy individuals and diseased people, particularly patients with multiple sclerosis (MS) and other white matter disorders. She is currently conducting and coordinating several national and international projects in adult and pediatric populations. She is also extensively applying advanced methods of analysis in an attempt to improve the understanding of the role of brain functional and structural plasticity in the different phases of MS, and the influence of pharmacological and rehabilitative interventions on brain reorganization. Prof. Rocca is member of various national and international Scientific Societies and, in some of them, she covered or is covering institutional roles. She has been chair of the MAGNIMS network since 2018, and is author or co-author of 53 book chapters and more than 500 papers published on peer-reviewed journals. Brian G. Weinshenker, MD, is a professor of neurology at the University of Virginia. He arrived at UVA Health's neurology department in 2022 after 35 years of experience practicing, including 30 years as a neurologist at the Mayo Clinic in Rochester, MN. V. Wee Yong, PhD, is a professor of translational neuroscience at the Hotchkiss Brain Institute and the Departments of Clinical Neurosciences and Oncology at The University of Calgary. He co-directs the Multiple Sclerosis (MS) Program of the Hotchkiss Brain Institute, and he holds the Canada Research Chair in Neuroimmunology.
1. The story and iconography of MS
2. The course and cost of MS
3. Definition of progressive MS
4. Health economics of MS and its treatment
5. The clinical features and diagnosis of MS
6. The prodrome of MS
7. MS in children and the elderly
8. Assessment of the eye in MS
9. Neuromyelitis opcitca and anti-MOG disease
10. The pathogenesis of MS
11. The treatment of MS
12. Models of care for the patient with MS
13. Monitoring the treatment of MS?
| Erscheint lt. Verlag | 8.4.2026 |
|---|---|
| Verlagsort | Philadelphia |
| Sprache | englisch |
| Maße | 216 x 276 mm |
| Gewicht | 450 g |
| Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Neurologie |
| Medizin / Pharmazie ► Medizinische Fachgebiete ► Schmerztherapie | |
| Studium ► 1. Studienabschnitt (Vorklinik) ► Anatomie / Neuroanatomie | |
| ISBN-10 | 0-323-93634-2 / 0323936342 |
| ISBN-13 | 978-0-323-93634-7 / 9780323936347 |
| Zustand | Neuware |
| Informationen gemäß Produktsicherheitsverordnung (GPSR) | |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
